By now we probably sound like a broken record when it comes to unusual options activity. But for the post I am going to write, our usual disclaimer makes a ton of sense: without intimate …
Continue readingFDA
This is the investment environment we live in. Celgene (CELG), a $98 billion market cap company that had $7.7 billion in sales in 2014, agrees to pay $7.3 billion for Receptos (RCPT), a biotech company …
Continue reading
On October 31st GILD shares were trading at new all time highs, gaining 57% on the year, or about $80 billion in market cap. Since those highs the stock has sold off almost 15%, and …
Continue reading
I don’t spend a lot of time on mid to small cap biotech stocks for one simple reason – because I don’t know the what, when or why. Throughout my career, I have seen a very small group trade/invest …
Continue reading
Or How I Learned To Stop Worrying and Let Apple Monitor my Body Apple has an annoying habit of bragging about new product releases as if they were the first company in the world to …
Continue reading
Abbvie has made several attempts in the past month to break above the $50 level, which it first touched in late October. The company had good Hepatitis C Treatment data in Phase III results released …
Continue reading
Abbott was one of the largest pharmaceutical companies in the world prior to its split in December 2012. The company spun off its proprietary pharmaceutical business (classic business of developing drugs for FDA approval and …
Continue reading
Dan and I were at a Stocktwits conference two weeks ago in San Diego and one of the presenters was going over some charts in the market over the past year. He got to a …
Continue readingVery tech heavy day in the options market today. INTC – The largest single options print of the day. The Dec / Jan13 21 put calendar traded 48k times this morning for 0.16. The customer …
Continue readingOn a day that saw big market weakness in the first hour of trading, and then choppy trading into the close, here are the large trades and heavy volume, that stuck out to us in …
Continue reading